{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:02:44Z","timestamp":1771034564768,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2407-14-937","type":"journal-article","created":{"date-parts":[[2014,12,11]],"date-time":"2014-12-11T22:01:53Z","timestamp":1418335313000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer"],"prefix":"10.1186","volume":"14","author":[{"given":"Yun","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f8rn","family":"Herrstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne","family":"Havsteen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene","family":"DePoint Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansoor Raza","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bente","family":"Lund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Maenpaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,11]]},"reference":[{"key":"5163_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60: 277-300. 10.3322\/caac.20073.","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 8","key":"5163_CR2","doi-asserted-by":"crossref","first-page":"viii7","DOI":"10.1093\/annonc\/mdi961","volume":"16","author":"A DuBois","year":"2005","unstructured":"DuBois A, Quinn M, Thigpen T, Vermorken J, Vall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla P, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt P, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, et al: 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005, 16 (Suppl 8): viii7-viii12.","journal-title":"Ann Oncol"},{"key":"5163_CR3","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1053\/j.seminoncol.2006.03.012","volume":"33","author":"J Pfisterer","year":"2006","unstructured":"Pfisterer J, Ledermann JA: Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol. 2006, 33: S12-S16.","journal-title":"Semin Oncol"},{"key":"5163_CR4","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","volume":"361","author":"MK Parmar","year":"2003","unstructured":"Parmar MK, Ledermann JA, Colombo N, Du BA, Delaloye JF, Kristensen GB, Wheeler S, Swart M, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trope C: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial. Lancet. 2003, 361: 2099-2106.","journal-title":"Lancet"},{"key":"5163_CR5","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003, 21: 3194-3200. 10.1200\/JCO.2003.02.153.","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"5163_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1634\/theoncologist.7-suppl_5-20","volume":"7","author":"DK Armstrong","year":"2002","unstructured":"Armstrong DK: Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist. 2002, 7 (Suppl 5): 20-28.","journal-title":"Oncologist"},{"key":"5163_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/00019053-200422060-00004","volume":"22","author":"G Dranitsaris","year":"2004","unstructured":"Dranitsaris G, Elia-Pacitti J, Cottrell W: Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer. Pharmacoeconomics. 2004, 22: 375-387. 10.2165\/00019053-200422060-00004.","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 3","key":"5163_CR8","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/annonc\/12.suppl_3.S3","volume":"12","author":"F Roila","year":"2001","unstructured":"Roila F, Cortesi E: Quality of life as a primary end point in oncology. Ann Oncol. 2001, 12 (Suppl 3): S3-S6. 10.1093\/annonc\/12.suppl_3.S3.","journal-title":"Ann Oncol"},{"key":"5163_CR9","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1093\/jnci\/djh323","volume":"96","author":"PA Vasey","year":"2004","unstructured":"Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004, 96: 1682-1691. 10.1093\/jnci\/djh323.","journal-title":"J Natl Cancer Inst"},{"key":"5163_CR10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.ygyno.2006.09.023","volume":"104","author":"HG Strauss","year":"2007","unstructured":"Strauss HG, Henze A, Teichmann A, Karbe I, Baumgart A, Thomssen C, Koelbl H: Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. Gynecol Oncol. 2007, 104: 612-616. 10.1016\/j.ygyno.2006.09.023.","journal-title":"Gynecol Oncol"},{"key":"5163_CR11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ygyno.2006.12.018","volume":"105","author":"DM Kushner","year":"2007","unstructured":"Kushner DM, Connor JP, Sanchez F, Volk M, Schink JC, Bailey HH, Harris LS, Stewart SL, Fine J, Hartenbach EM: Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol. 2007, 105: 358-364. 10.1016\/j.ygyno.2006.12.018.","journal-title":"Gynecol Oncol"},{"key":"5163_CR12","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","volume":"92","author":"I Vergote","year":"2000","unstructured":"Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, Friedlander M, Jakobsen A, Vermorken JB: Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer] Gynecologic Cancer Intergroup. J Natl Cancer Inst. 2000, 92: 1534-1535. 10.1093\/jnci\/92.18.1534.","journal-title":"J Natl Cancer Inst"},{"key":"5163_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000, 92: 205-216. 10.1093\/jnci\/92.3.205.","journal-title":"J Natl Cancer Inst"},{"key":"5163_CR14","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O\u2019Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989, 7: 1748-1756.","journal-title":"J Clin Oncol"},{"key":"5163_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron. 1976, 16: 31-41. 10.1159\/000180580.","journal-title":"Nephron"},{"key":"5163_CR16","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s12032-011-9878-z","volume":"29","author":"T Arimoto","year":"2012","unstructured":"Arimoto T, Nakagawa S, Oda K, Kawana K, Yasugi T, Taketani Y: Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer. Med Oncol. 2012, 29: 1253-1254. 10.1007\/s12032-011-9878-z.","journal-title":"Med Oncol"},{"key":"5163_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1212\/WNL.46.1.104","volume":"46","author":"PH Hilkens","year":"1996","unstructured":"Hilkens PH, Verweij J, Stoter G, Vecht CJ, van Putten WL, van den Bent MJ: Peripheral neurotoxicity induced by docetaxel. Neurology. 1996, 46: 104-108. 10.1212\/WNL.46.1.104.","journal-title":"Neurology"},{"key":"5163_CR18","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","volume":"28","author":"E Pujade-Lauraine","year":"2010","unstructured":"Pujade-Lauraine E, Wagner U, Avall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, Du Bois A: Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010, 28: 3323-3329. 10.1200\/JCO.2009.25.7519.","journal-title":"J Clin Oncol"},{"key":"5163_CR19","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1200\/JCO.2001.19.7.1901","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J: Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol. 2001, 19: 1901-1905.","journal-title":"J Clin Oncol"},{"key":"5163_CR20","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.ygyno.2003.12.004","volume":"92","author":"J Pfisterer","year":"2004","unstructured":"Pfisterer J, Du BA, Wagner U, Quaas J, Blohmer JU, Wallwiener D, Hilpert F: Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I\/II trial of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group. Gynecol Oncol. 2004, 92: 949-956. 10.1016\/j.ygyno.2003.12.004.","journal-title":"Gynecol Oncol"},{"key":"5163_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal LL, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011, 47: 8-32.","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"5163_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1525-1438.2005.15355.x","volume":"15","author":"J Pfisterer","year":"2005","unstructured":"Pfisterer J, Vergote I, Du BA, Eisenhauer E: Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer. 2005, 15 (Suppl 1): 36-41.","journal-title":"Int J Gynecol Cancer"},{"key":"5163_CR23","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","volume":"17","author":"M Markman","year":"1999","unstructured":"Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, Belinson J: Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999, 17: 1141-1145.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-937.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-14-937\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-937.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T07:23:55Z","timestamp":1630567435000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-14-937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["5163"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-14-937","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"13 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"937"}}